Umeclidinium bromide
- Generic Name
- Umeclidinium bromide
- Brand Names
- Anoro, Anoro Ellipta, Incruse Ellipta, Trelegy Ellipta, Rolufta Ellipta (previously Rolufta), Incruse Ellipta (previously Incruse)
- Drug Type
- Small Molecule
- Chemical Formula
- C29H34NO2
- CAS Number
- 869185-19-3
- Unique Ingredient Identifier
- GE2T1418SV
- Background
Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory volume in 1 second (FEV1) of less than 80%...
- Indication
Umeclidinium is approved by the FDA and Health Canada for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Additionally, umeclidinium also exists as combination products with vilanterol or vilanterol and fluticasone furoate. Both products were indicated for the maintenance treatment of COPD, but only the umeclidinium/v...
- Associated Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD)
- Associated Therapies
- -
ANTES B+ Clinical Trial
- Conditions
- Interventions
- Drug: Trelegy Ellipta 100/62.5/25Mcg Inh 30DDrug: BrimicaDrug: DuaklirDrug: UltibroDrug: UlunarDrug: XoternaDrug: AnoroDrug: LaventairDrug: Spiolto RespimatDrug: YanimoDrug: ForadilDrug: BroncoralDrug: Formoterol stadaDrug: OxisDrug: FormatrisDrug: Formoterol AldoDrug: OnbrezDrug: OslifDrug: HirobrizDrug: StriverdiDrug: BeglanDrug: BetamicanDrug: InaspirDrug: SereventDrug: SoltelDrug: EkliraDrug: BretarisDrug: SeebriDrug: TovanorDrug: EnurevDrug: SpirivaDrug: TavulusDrug: SirkavaDrug: BraltusDrug: GregalDrug: IncruseDrug: Rolufta
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Fundacio Privada Mon Clinic Barcelona
- Target Recruit Count
- 1028
- Registration Number
- NCT06282861
- Locations
- 🇪🇸
Hospital Clínic Barcelona, Barcelona, Catalunya, Spain
Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics
- Conditions
- Interventions
- First Posted Date
- 2016-12-23
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 95
- Registration Number
- NCT03002389
- Locations
- 🇺🇸
Roselove NUNOO-ASARE, Keswick, Virginia, United States
A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2018-02-09
- Lead Sponsor
- Stiefel, a GSK Company
- Target Recruit Count
- 58
- Registration Number
- NCT02673619
- Locations
- 🇨🇦
GSK Investigational Site, Montreal, Quebec, Canada
Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT02563899
- Locations
- 🇨🇦
GSK Investigational Site, Montreal, Quebec, Canada
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2018-05-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1036
- Registration Number
- NCT02236611
- Locations
- 🇸🇪
GSK Investigational Site, Stockholm, Sweden
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2018-01-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1017
- Registration Number
- NCT02207829
- Locations
- 🇺🇦
GSK Investigational Site, Zaporizhzhia, Ukraine
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.